Eli Lilly and Company (NYSE:LLY) Shares Bought by TrueWealth Advisors LLC

TrueWealth Advisors LLC raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 60.3% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,767 shares of the company's stock after acquiring an additional 665 shares during the quarter. TrueWealth Advisors LLC's holdings in Eli Lilly and Company were worth $1,364,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Retirement Wealth Solutions LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $119,000. 25 LLC lifted its holdings in shares of Eli Lilly and Company by 17.8% in the 4th quarter. 25 LLC now owns 305 shares of the company's stock worth $235,000 after buying an additional 46 shares during the period. Merit Financial Group LLC grew its position in shares of Eli Lilly and Company by 44.3% during the 4th quarter. Merit Financial Group LLC now owns 20,551 shares of the company's stock worth $15,865,000 after buying an additional 6,307 shares in the last quarter. Boston Common Asset Management LLC increased its stake in shares of Eli Lilly and Company by 29.4% during the fourth quarter. Boston Common Asset Management LLC now owns 24,028 shares of the company's stock valued at $18,550,000 after buying an additional 5,465 shares during the period. Finally, Relyea Zuckerberg Hanson LLC lifted its stake in Eli Lilly and Company by 11.9% in the fourth quarter. Relyea Zuckerberg Hanson LLC now owns 3,033 shares of the company's stock worth $2,342,000 after acquiring an additional 323 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the firm's stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.13% of the company's stock.

Wall Street Analyst Weigh In

LLY has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a "buy" rating for the company in a report on Monday, November 4th. Redburn Atlantic raised Eli Lilly and Company to a "hold" rating in a research report on Monday, November 4th. Sanford C. Bernstein initiated coverage on Eli Lilly and Company in a research report on Thursday, October 17th. They issued an "outperform" rating and a $1,100.00 price target for the company. Truist Financial lifted their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a "buy" rating in a research note on Thursday, October 10th. Finally, Barclays decreased their target price on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an "overweight" rating for the company in a research report on Thursday, October 31st. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $1,002.22.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded down $31.36 during trading on Friday, hitting $726.24. 5,497,108 shares of the company's stock were exchanged, compared to its average volume of 2,736,766. The stock has a market capitalization of $689.43 billion, a price-to-earnings ratio of 78.51, a PEG ratio of 1.66 and a beta of 0.41. The business has a 50-day simple moving average of $781.14 and a 200-day simple moving average of $854.35. Eli Lilly and Company has a 52-week low of $612.70 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts' consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion for the quarter, compared to analysts' expectations of $12.09 billion. During the same quarter in the previous year, the business posted $0.10 EPS. The business's quarterly revenue was up 20.4% on a year-over-year basis. On average, research analysts forecast that Eli Lilly and Company will post 13.14 EPS for the current year.

Eli Lilly and Company announced that its board has approved a stock buyback program on Monday, December 9th that permits the company to buyback $15.00 billion in shares. This buyback authorization permits the company to repurchase up to 2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's management believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.83%. The ex-dividend date is Friday, February 14th. This is a positive change from Eli Lilly and Company's previous quarterly dividend of $1.30. Eli Lilly and Company's dividend payout ratio is currently 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.